US-based Edwards Lifesciences has received CE Mark approval for its Acumen Hypotension Probability Indicator (HPI), which is developed to alert clinicians to potential hypotension, or abnormally low-blood pressure while a patient undergoes surgical and critical care.
Compatible on Edwards' minimally invasive and hemodynamic monitoring solutions, the HPI is comprised of a hypotension probability parameter which is instrumental in indicating hypotensive occurrences using machine learning techniques developed from more than 20,000 past patient events.
An alarm, fitted into the system, warns clinicians when hypotension probability exceeds the limit and a secondary screen visually connects blood pressure to hemodynamic flow parameters, such as cardiac output and contractility.
HPI is part of Edwards Acumen decision-support software suite and is run by the minimally invasive FloTrac IQ sensor, within the IQ family of hemodynamic solutions.
Edwards corporate critical care vice-president Catherine Szyman said: "European commercial release of the Acumen Hypotension Probability Indicator builds on a strong foundation of innovation and provides clinicians with the insights to help them make decisions earlier.”
The company is planning to commercially launch HPI in Europe this year and a worldwide launch slated next year.